Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2019; 25(21): 2539-2548
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2539
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2539
Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics
Michiel Dirk Voskuil, Amber Bangma, Rinse Karel Weersma, Eleonora Anna Margaretha Festen, Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen 9713 GZ, the Netherlands
Michiel Dirk Voskuil, Amber Bangma, Eleonora Anna Margaretha Festen, Department of Genetics, University of Groningen and University Medical Center Groningen, Groningen 9713 GZ, the Netherlands
Author contributions: All authors participated in literature search and writing of the manuscript. All authors approved the final version of the manuscript.
Conflict-of-interest statement: R.K.W. received unrestricted research grants from Takeda, Tramedico and Ferring. E.A.M.F. received an unrestricted research grant from Takeda. The remaining authors disclose no conflicts.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Michiel Dirk Voskuil, MD, Research Fellow, Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, PO Box 30001, Hanzeplein 1, Groningen 9713 GZ, the Netherlands. m.d.voskuil@umcg.nl
Telephone: +31-50-3610426 Fax: +31-50-3619306
Received: January 29, 2019
Peer-review started: January 29, 2019
First decision: March 27, 2019
Revised: March 28, 2019
Accepted: April 19, 2019
Article in press: April 20, 2019
Published online: June 7, 2019
Peer-review started: January 29, 2019
First decision: March 27, 2019
Revised: March 28, 2019
Accepted: April 19, 2019
Article in press: April 20, 2019
Published online: June 7, 2019
Core Tip
Core tip: In recent years, strong pharmacogenetic associations for drugs used in the management of inflammatory bowel disease (IBD) have been identified. However, the implementation of pre-treatment pharmacogenetic testing into clinical guidelines has been challenging. Particular groups of patients are needlessly exposed to (expensive) drugs that are either ineffective or harmful. Pre-treatment screening for TPMT and NUDT15 genetic variation should be incorporated into clinical IBD management guidelines. Therapeutic recommendations based on HLA genetic variants, conferring risk for thiopurine-induced pancreatitis and immunogenicity to tumor necrosis factor-antagonists, respectively, should be further evaluated.